Biodesix Q3 2024 Earnings Report

Biodesix EPS Results

• Actual EPS: -$0.07
• Consensus EPS: -$0.07
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.12

Biodesix Revenue Results

• Actual Revenue: $18.15 million
• Expected Revenue: $18.45 million
• Beat/Miss: Missed by -$300.00 thousand
• YoY Revenue Growth: N/A

Biodesix Announcement Details

• Quarter: Q3 2024
• Date: 11/1/2024
• Time: Before Market Opens

Biodesix (NASDAQ:BDSX) operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.